[1] 胡祥鹏,许建明,胡咏梅,等. CYP2C19基因多态性对奥美拉唑在中国人体内的药物动力学和药效学的影响[J]. 中国药理学通报,2005, 21(10): 1210-1213. [2] Tian X,Qiao HL,Li Y,et al.Pharmacokinetics of pantoprazole and lansoprazole in Chinese Hans in relation to CYP2C19 genotype[J].Chin J New Drugs Clin Rem,2009,28(2) :124-129. [3] Kita T, Sakaeda T, Baba T, et al. Different contribution of CYP2C19 in the in vitro metabolism of three proton pump inhibitors [J]. Biol Pharm Bull, 2003, 26(3): 386-390. [4] Ishizaki T, Horai Y. Review article: cytochrome P450 and the metabolism of proton pump inhibitors-emphasis on rabeprazole[J]. Aliment Pharmacol Ther, 1999, 13(Suppl 3):27-36. [5] Williams MP, Sercombe J, Hamilton MI, et al. A placebo-controlled trial to assess the effects of 8 days of dosing with rabeprazole versus omeprazole on 24 h intragastric acidity and serum gastrin concentrations in young healthy male subjects[J]. Aliment Pharmacol Ther, 1998, 12(11):1079-1089. [6] Morgan D. Intravenous proton pump inhibitors in the critical care setting[J]. Crit Care Med, 2002, 30 (Suppl 6):369-372. [7] Trepanier EF. Intravenous pantoprazole:a new tool for acutely ill patients who require acid suppression[J]. Can J Gastroenterol, 2000, 14 (Suppl D): 11D-20D. [8] Barkun A, Bardou M, Marshall JK. Consensus recommendations for managing patients with nonvariceal upper gastrointestinal bleeding[J]. Ann Intern Med, 2003, 139(10):843-857. [9] 龚均,张权,张燕,等.24 h胃内pH的节律研究[J].西安医科大学学报, 1999,20(3):326. [10] 王吉耀,廖二元. 内科学[M]. 2008:546. [11] Norris V, Baisley K, Dunn K, et al. Combined analysis of three crossover clinical pharmacology studies of effects of rabeprazole and esomeprazole on 24-h intragastric pH in healthy volunteers[J]. Alimentary Pharmcol Ther, 2007, 25(4):501-510. |